GSK Just Paid $10.6 Billion for This Precision Oncology Bet — Here’s What It Signals
The Nuvalent acquisition is the biggest biopharma deal of the week — and it’s rewriting the playbook for lung cancer investing.
Anthropic’s Near-Trillion Dollar IPO Filing Is Repricing Everything. Here’s What Investors Actually Own.
The Claude maker confidentially filed its S-1 at a $965B valuation. The real story isn’t Anthropic — it’s what this does to the listed AI complex.
The AI Infrastructure Stock Jensen Huang Just Put on Every Radar
Marvell Technology (MRVL) may be the most important chip company most investors still haven’t fully priced.
Eli Lilly Just Became Something Bigger Than a Drug Company
Q1 blowout, raised guidance, oral GLP-1 coverage expansion — LLY is redefining what a pharmaceutical platform looks like.
Marvell Technology Just Got the Most Powerful Endorsement in Semiconductors
Jensen Huang called MRVL “the next trillion-dollar company” — what that actually means for investors
Gold Miners Are Printing Cash at $4,700 Gold. The Stocks Are Barely Keeping Up.
Newmont just posted $3.1 billion in free cash flow in a single quarter. The market hasn’t fully noticed.
CrowdStrike Just Split Its Stock. Here’s What the Valuation Debate Is Really About.
The cybersecurity leader crossed $5 billion in ARR and announced a 4-for-1 stock split. The post-earnings selloff may be the setup.
Amazon Is Quietly Becoming the Most Important Stock in the AI IPO Wave
Before Anthropic trades publicly, there’s already a trillion-dollar infrastructure play sitting in plain sight
The Rotation Is Real — Healthcare and Financials Just Took the Wheel From Tech
The Dow hit a record 51,561. The Nasdaq barely moved. That divergence is the trade setup traders need to understand right now.
Marvell Is the Name Everyone Is Watching Right Now — Here’s What the Numbers Say
Jensen Huang’s trillion-dollar declaration at Computex 2026 ignited MRVL’s biggest single-day gain ever. The trade is real. The valuation debate is just getting started.